**Platelet microparticles in relation to disease-related risk factors in polycythemia vera and essential thrombocytosis**

Mohamed Hussam Aswad 1,2, Jarmila Kissova 1,2, Petra Ovesna 3, Miroslav Penka 1,2

1 Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno

2 Faculty of Medicine, Masaryk University

3 Institute of Biostatics and Analyses, Faculty of Medicine, Masaryk University, Brno

**Abstract**

**Introduction:**

Thromboembolism is a common life-threatening complication in patients with polycythemia vera (PV) and essential thrombocythemia (ET), accounting for a mortality rate of 41% and 26% of patients with an incidence rate of 3.8% and 1.9% per year, respectively. Besides older age and history of thrombosis being the definite risk factors of thrombosis, disease-related factors, such as JAK2V617F mutation and blood count results, have been linked to the increased risk of thrombosis. Circulating microparticles (MPs) may contribute to thrombosis through expressing pro-coagulant phosphatidylserine and tissue factor.

**Patients and methods:**

The absolute count of platelet microparticles (PMPs) and MPs procoagulant activity (MP-activity) were evaluated in relation to disease-related thrombotic risk factors in a cohort of 170 patients (51 with PV and 119 with ET). MP-activity was measured by the Zymuphen functional assay in 363 samples. PMPs were enumerated by flow cytometry in 466 samples.

**Results:**

Compared to healthy individuals, patients with ET or PV have significantly higher MPs levels. The pathological values of MP-activity are significantly higher in PV patients than in ET patients. Regarding disease-related risk factors, the presence of JAK2V617F mutation is associated with a significantly higher PMPs count. During the follow-up, patients who had their hematocrit value >45%, platelet count >400×109/L, or leukocytes count >10×109/L have significantly increased MPs levels. Patients with a history of thrombosis before PV or ET diagnosis have significantly higher MP-activity values than thrombosis-free patients. Treatment during the follow-up probably affects MPs levels as patients with arterial or venous thrombotic complications after diagnosis have significantly lower MPs values.

**Conclusion:**

Levels of platelet microparticles and their procoagulant activity are increased in disease-related risk factors for thrombosis, and this relationship indicates a possible role of MPs in thrombotic complications of patients with polycythemia vera and essential thrombocythemia.

# **Acknowledgment**:

Supported by MH CZ–DRO (FNBr–65269705).